FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 574 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... November 14, 2024 TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 Five Questions with…Jennifer. March 24, 2022 Load more HOT NEWS Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... Home Is Where the Heart Is Cómo encontrar la fuerza interior me ayudó a recuperarme del cáncer Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for...
